Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: Clinical importance and the effect of daunorubicin

British Journal of Haematology

Volumn 97, Issue 3, 1997, Pages 603-606

  Lilleyman, J S ^a   Gibson, B E S ^b   Stevens, R F ^c   Will, A M ^c   Hann, I M ^d   Richards, S M ^e   Hill, F G H ^f  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^f BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

childhood lymphoblastic leukaemia; daunorubicin; prognosis

Indexed keywords

DAUNORUBICIN;

ADULT; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER SURVIVAL; CELL INFILTRATION; DRUG EFFECT; FEMALE; HUMAN; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030909896     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.1002914.x     Document Type: Article

References (10)

1. Chessells, J., Bailey C. & Richards, S. (1994) Intensification of treatment and survival in all children with lymphoblastic leukaemia. Lancet, 345, 143-148.
2. Hen, O.B., Lilleyman, J.S., Shaw, M.P. & Peto, J. (1991) Results of the Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology, 78, 187-196.
3. Gaynon, P.S., Bleyer, W.A., Steinherz, P.G., Finkelstein, J.Z., Littman, P., Miller, D.R., Reaman, G., Sather, H. & Hammond, G.D. (1990) Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavourable presenting features. Medical and Pediatric Oncology, 18, 273-279.
4. Gill, P.S., Espina, B.M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J.A., Liebman, H.A., Forssen, E., Ross, M.E. & Levine, A.M. (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. Journal of Clinical Oncology, 13, 996-1003.
5. Hale, J.P. & Lewis, I.J. (1994) Anthracyclines: cardiotoxicity and its prevention. Archives of Diseases in Childhood, 71, 457-462.
6. Miller, D.R., Leikin, S., Albo, V., Sather, H., Karon, M. & Hammond, D. (1983) Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. Cancer, 51, 1041-1049.
7. Miller, D.R., Coccia, P.F., Bleyer, W.A., Lukens, J.N., Siegel, S.E., Sather, H.N. & Hammond, G.D. (1989) Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. Journal of Clinical Oncology, 7, 1807-1815.
8. Siefert, C., Nesser, M. & Thompson, D. (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Annals of Pharmacotherapy, 28, 1063-1069.
9. Steinherz, L.J., Steinherz, P.G., Tan, C.T.C., Heller, G. & Murphy, M.L. (1991) Cardiac toxicity 4-20 years after completing anthracycline therapy. Journal of the American Medical Association, 266, 1672-1677.
10. Steinherz, P.G., Gaynon, P.S., Breneman, J.C., Cherlow, J.M., Grossman, N.J., Kersey, J.H., Johnstone, H.S., Sather, H.N., Trigg, M.E., Chappell, R., Hammond, D. & Bleyer, W.A. (1996) Cytoreduction and prognosis in acute lymphoblastic leukemia: the importance of early marrow response: report from the Childrens Cancer Group. Journal of Clinical Oncology, 14, 389-598.